Home Patent Forecast® Sectors Log In   Sign Up   Support   Contact  
Why Patent Forecast® What's Included Patent Forecast® Sectors Free Trial Pricing News Feed Subscribe Menu

Patent 10765658
Mastix, Llc

Oral Compositions Delivering Therapeutically Effective Amounts Of Cannabinoids

Oral compositions provide delivery of cannabinoids to a subject. The oral compare chewable, fast- or slow-dissolving once placed in the mouth of a subject.

Much More than Average Length Specification


1 Independent Claims

  • Claim 1. A composition consisting of: about 0.1% to about 20% by weight hemp oil extract, about 35% to about 80% by weight of a sugar alcohol, or a blend of sugar alcohols, about1% to about 20% by weight of flavoring, about 0.1% to about 10% by weight of tableting lubricants and powder flow agents, about 0.01% to about 2% by weight of intensive sweeteners, and about 5% to about 25% of a gum base, based on the total weight of thecomposition.
  • Claim 4. A composition for treating a disease or disorder associated with abnormal mitogen-activated protein (MAP) kinase activity or levels wherein the composition comprises hemp oil, sugar alcohol, a blend of sugar alcohols, a gum base, orcombinations thereof, wherein the composition, based on the total weight of the composition, comprises: about 0.1% to about 20% by weight hemp oil extract, about 35% to about 80% by weight of a sugar alcohol, or a blend of sugar alcohols, and about 5% toabout 25% of a gum base.
  • Claim 7. A method of treating a disease or disorder associated with abnormal or increased mitogen-activated protein (MAP) kinase activity or levels in a subject, comprising: administering to a subject in need thereof, a gum-based composition forchewing, the composition consisting of: about 0.1% to about 20% by weight hemp oil extract, about 35% to about 80% by weight of a sugar alcohol, or a blend of sugar alcohols, about 1% to about 20% by weight of flavoring, about 0.1% to about 10% by weightof tableting lubricants and powder flow agents, about 0.01% to about 2% by weight of intensive sweeteners, and about 5% to about 25% of a gum base, based on the total weight of the composition, wherein the disease or disorder associated with abnormal orincreased mitogen-activated protein (MAP) kinase activity or levels in the subject is selected from the group consisting of a neuroinflammatory disease or disorder, migraines, epilepsy, neuropathic pain, general pain, joint pain, head trauma, orcombinations thereof.